BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One 2016;11:e0164076. [PMID: 27792741 DOI: 10.1371/journal.pone.0164076] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 Pastori D, Pignatelli P, Cribari F, Carnevale R, Saliola M, Violi F, Lip GY. Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists–naive patients with atrial fibrillation. American Heart Journal 2018;200:32-6. [DOI: 10.1016/j.ahj.2018.03.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
2 Krittayaphong R, Boonyapiphat T, Wongvipaporn C, Sairat P; COOL-AF Investigators. Age-Related Clinical Outcomes of Patients with Non-Valvular Atrial Fibrillation: Insights from the COOL-AF Registry. Clin Interv Aging 2021;16:707-19. [PMID: 33953549 DOI: 10.2147/CIA.S302389] [Reference Citation Analysis]
3 Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD‐AF Investigators. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. J Am Heart Assoc 2019;8:e010510. [PMID: 30717616 DOI: 10.1161/JAHA.118.010510] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
4 Iturbe-Hernandez T, García de Guadiana Romualdo L, Gil Ortega I, Martínez Francés A, Meca Birlanga O, Cerezo-Manchado JJ. Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol. Drugs Context 2020;9:2020-8-3. [PMID: 33014097 DOI: 10.7573/dic.2020-8-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Shambu SK, B SPS, Gona OJ, Desai N, B M, Madhan R, V R. Implementation and Evaluation of Virtual Anticoagulation Clinic Care to Provide Incessant Care During COVID-19 Times in an Indian Tertiary Care Teaching Hospital. Front Cardiovasc Med 2021;8:648265. [PMID: 33855052 DOI: 10.3389/fcvm.2021.648265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.Medicina (Kaunas). 2019;55. [PMID: 30650565 DOI: 10.3390/medicina55010015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wang W, Saczynski J, Lessard D, Mailhot T, Barton B, Waring ME, Sogade F, Hayward R, Helm R, McManus DD. Physical, cognitive, and psychosocial conditions in relation to anticoagulation satisfaction among elderly adults with atrial fibrillation: The SAGE-AF study. J Cardiovasc Electrophysiol 2019;30:2508-15. [PMID: 31515920 DOI: 10.1111/jce.14176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Barbieri MA, Cutroneo PM, Baratelli C, Cicala G, Battaglia A, Santoro V, Andò G, Spina E. Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database. J Clin Pharm Ther 2021;46:1027-40. [PMID: 33646603 DOI: 10.1111/jcpt.13391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lin Y, Xiong H, Su J, Lin J, Zhou Q, Lin M, Zhao W, Peng F. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation. Heart Vessels 2022. [PMID: 35041061 DOI: 10.1007/s00380-022-02021-2] [Reference Citation Analysis]
10 Barrios V, Cinza-Sanjurjo S, Gavín O, Egocheaga I, Burgos-Pol R, Soto J, Polanco C, Suárez J, Casado MÁ. Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain. Rev Esp Cardiol (Engl Ed) 2021;74:773-80. [PMID: 32980294 DOI: 10.1016/j.rec.2020.06.033] [Reference Citation Analysis]
11 Khatib R, Ludwikowska M, Witt DM, Ansell J, Clark NP, Holbrook A, Wiercioch W, Schünemann H, Nieuwlaat R. Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. Blood Adv 2019;3:789-96. [PMID: 30850385 DOI: 10.1182/bloodadvances.2018025163] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
12 Wertheimer G, Bereznicki LR. Exploring the Quality of Anticoagulant Prescribed for Patients With Atrial Fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia. J Cardiovasc Pharmacol Ther 2019;24:46-53. [PMID: 29962220 DOI: 10.1177/1074248418786264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ng DL, Malik NMBA, Chai CS, Goh GM, Tan SB, Bee PC, Gan GG, Said AB. Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study. Health Qual Life Outcomes 2020;18:347. [PMID: 33081816 DOI: 10.1186/s12955-020-01600-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Proietti M, Romiti GF, Olshansky B, Lip GY. Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation: The AFFIRM Study (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). Hypertension 2017;70:949-58. [DOI: 10.1161/hypertensionaha.117.10106] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 García-Sempere A, Hurtado I, Bejarano-Quisoboni D, Rodríguez-Bernal C, Santa-Ana Y, Peiró S, Sanfélix-Gimeno G. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study. PLoS One 2019;14:e0211681. [PMID: 30753227 DOI: 10.1371/journal.pone.0211681] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
16 Li Y, Lip GY. Stroke prevention in atrial fibrillation: State of the art. International Journal of Cardiology 2019;287:201-9. [DOI: 10.1016/j.ijcard.2018.09.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ferreira T, Huber SC, de Moraes Martinelli B, Junior AL, Menezes FH, Orsi FA, Bittar LF, de Oliveira LFG, Sodre LR, Mello TT, Rielli G, Colella MP, de Paula EV, Yamaguti-hayakawa GG, Montalvão S, Annichino-bizzacchi JM. Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban. Vascular Pharmacology 2020;124:106608. [DOI: 10.1016/j.vph.2019.106608] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
18 Pastori D, Farcomeni A, Saliola M, Del Sole F, Pignatelli P, Violi F, Lip GYH; ATHERO-AF Study Group. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. Eur J Intern Med 2018;54:34-9. [PMID: 29655807 DOI: 10.1016/j.ejim.2018.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
19 Mwita JC, Francis JM, Oyekunle AA, Gaenamong M, Goepamang M, Magafu MGMD. Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana.Clin Appl Thromb Hemost. 2018;24:596-601. [PMID: 29258394 DOI: 10.1177/1076029617747413] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
20 Andrade JG, Macle L, Nattel S, Verma A, Cairns J. Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. Can J Cardiol. 2017;33:965-976. [PMID: 28754397 DOI: 10.1016/j.cjca.2017.06.002] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 12.0] [Reference Citation Analysis]
21 Bonde AN, Staerk L, Lee CJ, Vinding NE, Bang CN, Torp-Pedersen C, Gislason G, Lip GYH, Olesen JB. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control. J Am Coll Cardiol 2018;72:1357-65. [PMID: 30213328 DOI: 10.1016/j.jacc.2018.06.065] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
22 Apiyasawat S, Kornbongkotmas S, Chichareon P, Krittayaphong R; COOL‐AF Investigators. Mortality risk and temporal patterns of atrial fibrillation in the nationwide registry. J Arrhythm 2021;37:1434-42. [PMID: 34887947 DOI: 10.1002/joa3.12643] [Reference Citation Analysis]
23 Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation 2019;139:787-98. [PMID: 30586740 DOI: 10.1161/CIRCULATIONAHA.118.035012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 11.7] [Reference Citation Analysis]
24 Camm AJ, Cools F, Virdone S, Bassand J, Fitzmaurice DA, Arthur Fox KA, Goldhaber SZ, Goto S, Haas S, Mantovani LG, Kayani G, Grierson Turpie AG, Antoon Verheugt FW, Kakkar AK. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. Journal of the American College of Cardiology 2020;76:1425-36. [DOI: 10.1016/j.jacc.2020.07.045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
25 Audurier Y, Chapet N, Renaudin P, Bons C, Mathieu B, Theret S, de Barry G, Jalabert A, Breuker C, Leclercq F, Pasquie JL, Agullo A, Roubille F, Castet-Nicolas A. Collaboration between cardiologist and clinical pharmacist on prescription quality: What is the potential clinical impact for cardiology patients? Int J Clin Pract 2020;74:e13531. [PMID: 32459398 DOI: 10.1111/ijcp.13531] [Reference Citation Analysis]
26 Huang YL, Chen CY, Chu CC. Risk of major bleeding and thromboembolism in Asian patients with nonvalvular atrial fibrillation using direct oral anticoagulants versus warfarin. Int J Clin Pharm 2021. [PMID: 34324128 DOI: 10.1007/s11096-021-01309-z] [Reference Citation Analysis]
27 Krittayaphong R, Kunjara-Na-Ayudhya R, Ngamjanyaporn P, Boonyaratavej S, Komoltri C, Yindeengam A, Sritara P, Lip GYH, For The Cool-Af Investigators. Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand. J Geriatr Cardiol 2020;17:612-20. [PMID: 33224180 DOI: 10.11909/j.issn.1671-5411.2020.10.004] [Reference Citation Analysis]
28 Lobato SM, Tarrazo CT, Fernández EG, Alcalá MM. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain. Future Cardiology 2018;14:17-24. [DOI: 10.2217/fca-2018-0022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Jerjes-Sanchez C, Corbalan R, Barretto ACP, Luciardi HL, Allu J, Illingworth L, Pieper KS, Kayani G; GARFIELD-AF Investigators. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. Clin Cardiol 2019;42:553-60. [PMID: 30873623 DOI: 10.1002/clc.23176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
30 Neumann I, Schünemann HJ, Bero L, Cooke G, Magrini N, Moja L. Global access to affordable direct oral anticoagulants. Bull World Health Organ 2021;99:653-60. [PMID: 34475602 DOI: 10.2471/BLT.20.278473] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Krittayaphong R, Winijkul A, Pirapatdit A, Chiewvit P, Komoltri C, Boonyapisit W, Arunsiriwattana S, Bunyapipat T, Apiyasawat S, Rattanasumawong K, Yindeengam A; Cool-AF Investigators. SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. Singapore Med J 2020;61:641-6. [PMID: 31680175 DOI: 10.11622/smedj.2019143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, Sharan L, Allen LaPointe NM, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al-Khatib SM, Sanders GD. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. Thromb Haemost 2018;118:2171-87. [PMID: 30376678 DOI: 10.1055/s-0038-1675400] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 20.5] [Reference Citation Analysis]
33 García-Sempere A, Hurtado I, Bejarano D, Santa-Ana Y, Rodríguez-Bernal C, Peiró S, Sanfélix-Gimeno G. Group-based Trajectory Models to Assess Quality of INR Control and Its Association With Clinical Outcomes. Med Care 2020;58:e23-30. [PMID: 31764479 DOI: 10.1097/MLR.0000000000001253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Proietti M, Lip GY. Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. International Journal of Cardiology 2018;252:96-100. [DOI: 10.1016/j.ijcard.2017.10.091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
35 Camm AJ, Fox KAA, Virdone S, Bassand JP, Fitzmaurice DA, Berchuck SI, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Cappato R, Kakkar AK; GARFIELD-AF investigators. Comparative effectiveness of oral anticoagulants in everyday practice. Heart 2021:heartjnl-2020-318420. [PMID: 33593994 DOI: 10.1136/heartjnl-2020-318420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
36 Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, Roldán V, Muñiz J, Raña-Míguez P, Ruiz-Ortiz M, Cequier Á, Bertomeu-Martínez V, Badimón L, Anguita M, Lip GYH, Marín F; FANTASIIA Investigators. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace 2018;20:1435-41. [PMID: 29095971 DOI: 10.1093/europace/eux314] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
37 Masresha N, Muche EA, Atnafu A, Abdela O. Evaluation of Warfarin Anticoagulation at University of Gondar Comprehensive Specialized Hospital, North-West Ethiopia. J Blood Med 2021;12:189-95. [PMID: 33790682 DOI: 10.2147/JBM.S282948] [Reference Citation Analysis]
38 Edmiston MK, Lewis WR. Bleeding Risk Scores in Atrial Fibrillation: Helpful or Harmful? J Am Heart Assoc 2018;7:e010582. [PMID: 30371216 DOI: 10.1161/JAHA.118.010582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Schaeffer B, Rüden L, Salzbrunn T, Pinnschmidt HO, Akbulak RÖ, Moser JM, Jularic M, Meyer C, Eickholt C, Sultan A, Lüker J, Steven D, Willems S, Hoffmann BA. Incidence of intracardiac thrombus formation prior to electrical cardioversion in respect to the mode of oral anticoagulation. J Cardiovasc Electrophysiol 2018;29:537-47. [DOI: 10.1111/jce.13447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
40 Goto S, Goto S, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, Misselwitz F, Turpie AGG, Verheugt FWA, Fox KAA, Gersh BJ, Kakkar AK. New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. Eur Heart J Cardiovasc Pharmacother 2020;6:301-9. [PMID: 31821482 DOI: 10.1093/ehjcvp/pvz076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
41 Rojo M, Roco AM, Suarez M, Lavanderos MA, Verón G, Bertoglia MP, Arredondo A, Nieto E, Rubilar JC, Tamayo F, Cruz D, Muñoz J, Bravo G, Salas P, Mejías F, Véliz P, Godoy G, Varela NM, Llull G, Quiñones LA. Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. Clin Appl Thromb Hemost 2020;26:1076029620909154. [PMID: 32228310 DOI: 10.1177/1076029620909154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GYH. Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. J Clin Med 2020;9:E1698. [PMID: 32498302 DOI: 10.3390/jcm9061698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Pokorney SD, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Reiffel JA, Singer DE, Freeman JV, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli GV, Ezekowitz MD, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiol 2019;4:756-64. [PMID: 31268487 DOI: 10.1001/jamacardio.2019.1960] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Nieto E, Suarez M, Roco Á, Rubilar JC, Tamayo F, Rojo M, Verón G, Sepúlveda J, Mejías F, Salas P, Góngora M, Andrade P, Canales A, Carabantes J, Cruz D, Contreras E, Pavez D, Charo P, Bravo G, Calderón J, Gallardo C, Vega P, Quiñones LA. Anticoagulation Management With Coumarinic Drugs in Chilean Patients. Clin Appl Thromb Hemost 2019;25:1076029619834342. [PMID: 30880431 DOI: 10.1177/1076029619834342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Solla-Ruiz I, Villanueva-Benito I, Paredes-Galán E, Salterain-González N, Oria-González G, De La Cuesta-Arzamendi F, Querejeta-Iraola R. Differences between patient-driven adherence to vitamin K antagonists and direct oral anticoagulants. Do few missed doses matter? ACO-MEMS Study. Thromb Res 2019;179:20-7. [PMID: 31075697 DOI: 10.1016/j.thromres.2019.04.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
46 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
47 Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Marín F, Lip GYH. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clin Ther 2018;40:114-22. [PMID: 29275065 DOI: 10.1016/j.clinthera.2017.11.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
48 Roldán Rabadán I, Esteve-pastor MA, Anguita-sánchez M, Muñiz J, Camacho Siles J, Quesada MA, Ruiz Ortiz M, Marín F, Martínez Sellés M, Bertomeu V, Lip GY, Cequier Fillat A, Badimón L; the FANTASIIA Study Investigators. Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from FANTASIIA Registry. Eur J Clin Invest 2018;48:e12910. [DOI: 10.1111/eci.12910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
49 Qiu R, Hu J, Huang Y, Han S, Zhong C, Li M, He T, Lin Y, Guan M, Chen J, Shang H. Outcome reporting from clinical trials of non-valvular atrial fibrillation treated with traditional Chinese medicine or Western medicine: a systematic review. BMJ Open 2019;9:e028803. [PMID: 31471437 DOI: 10.1136/bmjopen-2018-028803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Mitsuntisuk P, Nathisuwan S, Junpanichjaroen A, Wongcharoen W, Phrommintikul A, Wattanaruengchai P, Rattanavipanon W, Chulavatnatol S, Chaiyakunapruk N, Likittanasombat K, Lip GYH. Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country. Clin Pharmacol Ther 2021;109:1282-92. [PMID: 33113153 DOI: 10.1002/cpt.2090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Rivera-Caravaca JM, Badimón L, Ferreira-Gonzalez I, Gómez-Doblas JJ, Roca-Luque I, Lekuona I, Jiménez-Candil J, Rodríguez-Padial L, González-Juanatey C, Calvo-Jambrina R, Fácila L, Ruiz-Ortiz M, Anguita M, Marín F. Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry. Europace 2021:euab131. [PMID: 34115857 DOI: 10.1093/europace/euab131] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Lip GY, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L. Antithrombotic Therapy for Atrial Fibrillation. Chest 2018;154:1121-201. [DOI: 10.1016/j.chest.2018.07.040] [Cited by in Crossref: 397] [Cited by in F6Publishing: 344] [Article Influence: 99.3] [Reference Citation Analysis]
53 Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. Am J Med 2018;131:1359-1366.e6. [PMID: 30153428 DOI: 10.1016/j.amjmed.2018.06.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 15.8] [Reference Citation Analysis]
54 Roco A, Nieto E, Suárez M, Rojo M, Bertoglia MP, Verón G, Tamayo F, Arredondo A, Cruz D, Muñoz J, Bravo G, Salas P, Mejías F, Godoy G, Véliz P, Quiñones LA. A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study. Front Pharmacol 2020;11:325. [PMID: 32327994 DOI: 10.3389/fphar.2020.00325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
55 Rivera-caravaca JM, Esteve-pastor MA, Roldán V, Marín F, Lip GY. Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opinion on Drug Safety 2017;16:1051-62. [DOI: 10.1080/14740338.2017.1351542] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
56 Lacoste JL, Hansen CL. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting. Am J Health Syst Pharm 2019;76:1395-402. [PMID: 31505555 DOI: 10.1093/ajhp/zxz152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 van Miert JHA, Veeger NJGM, Ten Cate-Hoek AJ, Piersma-Wichers M, Meijer K. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study. PLoS One 2020;15:e0235639. [PMID: 32649714 DOI: 10.1371/journal.pone.0235639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Bassand JP, Apenteng PN, Atar D, Camm AJ, Cools F, Corbalan R, Fitzmaurice DA, Fox KA, Goto S, Haas S, Hacke W, Jerjes-Sanchez C, Koretsune Y, Heuzey JL, Sawhney JP, Oh S, Stępińska J, Cate VT, Verheugt FW, Kayani G, Pieper KS, Kakkar AK, Garfield-Af Investigators FT. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol 2021;17:19-38. [PMID: 32696663 DOI: 10.2217/fca-2020-0014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Oh S, Kim JS, Oh YS, Shin DG, Pak HN, Hwang GS, Choi KJ, Kim JB, Lee MY, Park HW, Kim DK, Jin ES, Park J, Oh IY, Shin DH, Park HS, Kim JH, Kim NH, Ahn MS, Seo BJ, Kim YJ, Kang S, Lee J, Kim YH. Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II. J Korean Med Sci 2018;33:e323. [PMID: 30505257 DOI: 10.3346/jkms.2018.33.e323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
60 Graves KG, May HT, Jacobs V, Bair TL, Stevens SM, Woller SC, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Peter Weiss J, Jared Bunch T. Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long-term warfarin. Am Heart J 2017;188:93-8. [PMID: 28577686 DOI: 10.1016/j.ahj.2017.02.026] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
61 Knežević A, Nadinić M, Užović Frakin I, Trkulja V. Poor warfarin anticoagulation in long-term thromboprophylaxis: a survey in a southern Croatian county. Croat Med J 2019;60:2-11. [PMID: 30825272 [PMID: 30825272 DOI: 10.3325/cmj.2019.60.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
62 Collins P, Lewin A, Vincze Irving N, Sylvester K, Fanikos J, Goldhaber SZ, Connors JM. Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. Crit Pathw Cardiol 2021;20:103-7. [PMID: 33337730 DOI: 10.1097/HPC.0000000000000251] [Reference Citation Analysis]
63 Wattanaruengchai P, Nathisuwan S, Karaketklang K, Wongcharoen W, Phrommintikul A, Lip GYH. Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants. Br J Clin Pharmacol 2021. [PMID: 34783372 DOI: 10.1111/bcp.15145] [Reference Citation Analysis]
64 Riva N, Meli S, Borg Xuereb C, Vella K, Ageno W, Makris M, Gatt A. Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. Thromb Res 2020;196:21-4. [PMID: 32823171 DOI: 10.1016/j.thromres.2020.07.050] [Reference Citation Analysis]
65 Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med 2021:bmjebm-2020-111634. [PMID: 34635480 DOI: 10.1136/bmjebm-2020-111634] [Reference Citation Analysis]
66 Kamthornthanakarn I, Krittayaphong R. Optimal INR level for warfarin therapy after mechanical mitral valve replacement. BMC Cardiovasc Disord 2019;19:97. [PMID: 31023235 DOI: 10.1186/s12872-019-1078-3] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
67 Suárez Fernández C, Castilla-Guerra L, Cantero Hinojosa J, Suriñach JM, Acosta de Bilbao F, Tamarit JJ, Diaz Diaz JL, Hernandez JL, Pose A, Montero-Pérez-Barquero M, Roquer J, Gállego J, Vivancos J, Mostaza JM. Satisfaction with oral anticoagulants in patients with atrial fibrillation. Patient Prefer Adherence 2018;12:267-74. [PMID: 29497282 DOI: 10.2147/PPA.S152109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
68 Escobar C, Camm AJ. Changing paradigms: from prevention of thromboembolic events to improved survival in patients with atrial fibrillation. Europace 2021;23:837-43. [PMID: 33221894 DOI: 10.1093/europace/euaa324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
69 Blanch P, Freixa-Pamias R, Gambau M, Lafuente R, Basile L. Impact of an oral anticoagulation self-monitoring and self-management program in patients with mechanical heart valve prosthesis. J Comp Eff Res 2021;10:307-14. [PMID: 33594899 DOI: 10.2217/cer-2020-0215] [Reference Citation Analysis]
70 Marietta M, Banchelli F, Pavesi P, Manotti C, Quintavalla R, Sinigaglia T, Guazzaloca G, Pattacini C, Urbinati S, Malavasi VL, Boriani G, Voci C, D'amico R, Magrini N. Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study. European Journal of Internal Medicine 2019;62:9-16. [DOI: 10.1016/j.ejim.2018.12.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
71 Rahme E, Godin R, Nedjar H, Dasgupta K, Tagalakis V. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. Thromb Res 2021;203:121-30. [PMID: 34000493 DOI: 10.1016/j.thromres.2021.05.005] [Reference Citation Analysis]
72 Gusdon AM, Farrokh S, Grotta JC. Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. Semin Neurol 2021. [PMID: 33851394 DOI: 10.1055/s-0041-1726331] [Reference Citation Analysis]